VRTX:NSD-Vertex Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 410.65

Change

+2.47 (+0.61)%

Market Cap

USD 120.60B

Volume

1.10M

Analyst Target

USD 306.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+2.21 (+0.31%)

USD 84.94B
ARGX argenx NV ADR

+2.05 (+0.33%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-0.75 (-0.31%)

USD 31.66B
BGNE BeiGene Ltd

+3.06 (+1.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+3.23 (+0.90%)

USD 16.18B
MRNA Moderna Inc

+0.16 (+0.40%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.17 (+0.67%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.28 (+1.47%)

USD 13.67B
INCY Incyte Corporation

-0.35 (-0.50%)

USD 13.52B
INSM Insmed Inc

+0.14 (+0.20%)

USD 13.20B

ETFs Containing VRTX

DCCHAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

USD 0.08B
DCUSAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
DCEUAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
DCGBAS:SW UBS (Irl) Fund Solutions .. 90.84 % 0.00 %

N/A

N/A
MSGR 8.22 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 7.99 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 7.95 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 7.68 % 0.00 %

N/A

USD 5.35M
UBIO 6.52 % 0.95 %

N/A

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.49 % 0.00 %

N/A

N/A
ZWHC:CA BMO Covered Call Health C.. 5.16 % 0.00 %

N/A

N/A
LIFE-U:CA Evolve Global Healthcare .. 5.00 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.94 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.91 % 0.00 %

N/A

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

N/A

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 4.83 % 0.00 %

N/A

N/A
XNNV:XETRA Xtrackers MSCI Innovation.. 4.76 % 0.00 %

N/A

N/A
PINK Simplify Exchange Traded .. 4.43 % 0.00 %

+0.27 (+0.37%)

USD 0.15B
ZPW:CA BMO US Put Write ETF 3.84 % 0.71 %

N/A

CAD 0.07B
HEAL:CA 3.39 % 0.00 %

N/A

N/A
CDNA:CA CI Bio-Revolution Index E.. 2.95 % 0.00 %

N/A

CAD 6.05M
BIOT:SW L&G Pharma Breakthrough U.. 2.68 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.44 % 0.00 %

N/A

USD 0.04B
UPWD 2.43 % 0.00 %

N/A

N/A
XDGI:XETRA Xtrackers MSCI Global SDG.. 2.38 % 0.00 %

N/A

USD 0.01B
POWA Invesco Bloomberg Pricing.. 2.11 % 0.00 %

+0.17 (+0.37%)

N/A
SAGP The Advisorsa Inner Circl.. 2.00 % 0.00 %

+0.11 (+0.37%)

USD 0.04B
XLVE:CA 1.93 % 0.00 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 1.73 % 1.14 %

+2.05 (+0.37%)

USD 0.82B
MVEA:SW iShares Edge MSCI USA Min.. 1.51 % 0.00 %

N/A

USD 0.33B
FLXU:SW Franklin U.S. Equity UCIT.. 1.17 % 0.00 %

N/A

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 1.03 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

+0.23 (+0.37%)

USD 0.42B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+0.58 (+0.37%)

USD 0.08B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-0.21 (0.37%)

USD 3.54M
DEF 0.00 % 0.59 %

N/A

N/A
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+0.76 (+0.37%)

N/A
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+0.72 (+0.37%)

USD 6.91B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

-0.16 (0.37%)

USD 0.04B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.39 (+0.37%)

N/A
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

+0.20 (+0.37%)

USD 0.21B
ZPW-U:CA BMO US Put Write ETF 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
VLQ:CA 0.00 % 0.40 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+0.67 (+0.37%)

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

+0.30 (+0.37%)

N/A
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

N/A

CAD 0.21B
HWWA:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

N/A

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
HWWD:LSE HSBC Multi Factor Worldwi.. 0.00 % 0.00 %

N/A

N/A
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
SMRT:PA 0.00 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
FLXU:F Franklin LibertyShares IC.. 0.00 % 0.00 %

N/A

N/A
SM8T:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
DBPD:XETRA Xtrackers ShortDAX x2 Dai.. 0.00 % 0.00 %

N/A

USD 0.13B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
SM8T:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 0.04B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
ZINN:CA 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
SMRU:PA Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

USD 3.65M
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

N/A

USD 1.13B
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

N/A

CAD 0.09B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

+0.10 (+0.37%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.92% 65% D 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.92% 65% D 47% F
Trailing 12 Months  
Capital Gain 0.34% 66% D+ 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.34% 66% D+ 46% F
Trailing 5 Years  
Capital Gain 85.84% 87% B+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 85.84% 87% B+ 82% B
Average Annual (5 Year Horizon)  
Capital Gain 16.56% 63% D 70% C-
Dividend Return 16.56% 63% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.83% 90% A- 67% D+
Risk Adjusted Return 61.75% 97% N/A 84% B
Market Capitalization 120.60B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.